Dr Reddy's Laboratories is acquiring the Dutch service-based specialty pharmaceutical firm, OctoPlus, for €27.39 million, as part of efforts to expand its technology capabilities in drug delivery and the custom pharmaceutical services business.
Dr Reddy's Laboratories is acquiring the Dutch service-based specialty pharmaceutical firm, OctoPlus, for €27.39 million, as part of efforts to expand its technology capabilities in drug delivery and the custom pharmaceutical services business.
Dr Reddy's expects to make a public offer for all issued and outstanding ordinary shares in the capital of OctoPlus...
Reimbursement rules are disincentivizing innovation, according to Vas Narasimhan.
Recent moves in the industry include changes at the top at Ascentage Pharma, Inventiva and Brenig Therapeutics, plus five companies get new CFOs.
As AI-driven firms like Insilico, big pharma like J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s respectively advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?
